MedTrace Logo

A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years Old

NCT04700618 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2022-02-16

No results posted yet for this study

Summary

Objective: To evaluate the safety and immunogenicity of PPV23 vaccine revaccinated in 60-70 years old in Shanghai.

Conditions

  • Vaccination

Interventions

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.

Sponsors & Collaborators

  • Shanghai Municipal Center for Disease Control and Prevention

    collaborator OTHER

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Xiang Guo · Shanghai Municipal Center for Disease Control and Prevention

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-21
Primary Completion
2021-08-22
Completion
2022-02-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04700618 on ClinicalTrials.gov